首页> 外文期刊>Current Issues in Pharmacy and Medical Sciences >Comparison of oral bioavailability of acetaminophen tablets, capsules and effervescent dosage forms in healthy volunteers
【24h】

Comparison of oral bioavailability of acetaminophen tablets, capsules and effervescent dosage forms in healthy volunteers

机译:对乙酰氨基酚片剂,胶囊剂和泡腾剂型在健康志愿者中口服生物利用度的比较

获取原文
           

摘要

A wide variety of acetaminophen dosage forms have been administered to relieve mild to moderate pain and fever, so far. The purpose of this study was to compare the oral bioavailability in healthy volunteers, of three of these dosage forms. We included healthy volunteers in our study and divided replace with placed them into three groups: tablet, capsule and effervescent. Each dosage form contained 500 mg of acetaminophen as active material. Blood samples were taken at 0.5, 1, 2, 4 and 8-hour intervals after receiving the dose. Acetaminophen blood levels were measured using HPLC method. Data were fit in a “one-compartment PK model”, using P-Pharm 1.5 software and analyzed under statistical tests. The maximum concentrations of acetaminophen in blood samples were measured at 1h after taking the drug (6.61±3.19 μg/ml, 11.29±3.94 μg/ml and 15.25±2.54 μg/ml in groups receiving capsule, tablet and effervescent, respectively). Pharmacokinetic (PK) data analysis & modeling from the three groups showed that the half-life of acetaminophen was 140.72 min in the tablet group, 140.29 min in capsule and 132.08 min in effervescent. The area under the blood levels curve were 47.04, 40.62 and 53.11 μgmin/ml, in tablet, capsule, and effervescent groups, respectively. Statistically significant differences in PK parameters were recorded as the study replace with we compared effervescent with tablets and capsule dosage forms (p < 0.05). According to the results, the effervescent form creates better PK parameters compared with tablet and capsule forms, therefore, it is suggested replace with we suggested that this form should be administer in cases of pain and fever to achieve quick drug efficacy.
机译:迄今为止,已经施用了多种对乙酰氨基酚剂型以减轻轻度至中度的疼痛和发烧。这项研究的目的是比较其中三种剂型在健康志愿者中的口服生物利用度。我们将健康志愿者纳入研究,并将其分为三组:片剂,胶囊剂和泡腾剂。每种剂型均包含500 mg对乙酰氨基酚作为活性物质。接受剂量后,每隔0.5、1、2、4和8小时采集一次血样。对乙酰氨基酚血液水平使用HPLC方法进行测量。使用P-Pharm 1.5软件将数据拟合到“一室PK模型”中,并在统计测试下进行分析。服用药物后1小时测量血样中对乙酰氨基酚的最大浓度(分别在接受胶囊,片剂和泡腾的组中分别为6.61±3.19μg/ ml,11.29±3.94μg/ ml和15.25±2.54μg/ ml)。三组药代动力学(PK)数据分析和建模显示,对乙酰氨基酚的半衰期在片剂组中为140.72分钟,在胶囊中为140.29分钟,在泡腾中为132.08分钟。在片剂,胶囊和泡腾剂组中,血药浓度曲线下的面积分别为47.04、40.62和53.11μgmin/ ml。随着研究的进行,我们记录了PK参数的统计学显着性差异,我们将泡腾片与片剂和胶囊剂型进行了比较(p <0.05)。根据结果​​,与片剂和胶囊剂相比,泡腾剂形式可产生更好的PK参数,因此建议将其代替,我们建议在疼痛和发烧的情况下应使用此形式,以达到快速的药效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号